Overview
BHST market data
Price History
BHST price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.93 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -76.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.14 – $0.38 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $67.8M · P/B 73.09 · P/S 3.02.
Company News
Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5Benzinga · Aug 12, 2026, 6:30 PM
Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8Benzinga · Aug 12, 2026, 6:04 PM
Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M EstBenzinga · Aug 11, 2026, 8:16 PM
BioHarvest Sciences shares are trading higher after the company reported Q2 financial results. The company revised its FY26 CDMO revenue guidance.Benzinga · Aug 11, 2026, 1:30 PM
BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42MBenzinga · Aug 11, 2026, 10:36 AM
BioHarvest Sciences Enters Agreement For A Rare, Endangered Fragrance Plant Cell Culture With A UAE-Based Customer; Sees $20M-$30M In 2027-28 SalesBenzinga · Aug 11, 2026, 10:09 AM
BioHarvest Sciences Inc. - Common Stock Q2 EPS $(0.17) Misses $(0.12) Estimate, Sales $8.837M Miss $9.537M EstimateBenzinga · Aug 11, 2026, 10:02 AM
BioHarvest Sciences Receives $1.4M Grant Approval From Israel Innovation AuthorityBenzinga · Jul 15, 2026, 11:35 AM
BioHarvest Sciences Expands Its Joint Sweetener Development Program With Tate & Lyle To Include Multiple Plant-Based Sweetener MoleculesBenzinga · May 18, 2026, 11:25 AM